Oseikon: Summary of 2026 Semi-annual Report
Beijing Aosaikang Pharmaceutical Co., Ltd. 2026 Semi-annual Report Summary Securities Code: 002755 Securities Abbreviation: Aosaikang Announcement Number: 2026-016
Beijing Aosaikang Pharmaceutical Co., Ltd. 2026 Semi-Annual Report Summary
Summary of the 2026 Semi-Annual Report of Beijing Aosaikang Pharmaceutical Co., Ltd.
1. Important tips
This summary of the semi-annual report comes from the full text of the semi-annual report. In order to fully understand the company's operating results, financial status and future development plans, investors should read the full text of the semi-annual report carefully in the media designated by the China Securities Regulatory Commission.
All directors have attended the board meeting where this report was considered.
Non-standard audit opinion tips
□ApplicableNot applicable
The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital reviewed by the board of directors
□ApplicableNot applicable
The company plans not to distribute cash dividends, give away bonus shares, or convert public reserve funds into share capital.
Preferred stock profit distribution plan for the reporting period approved by the board of directors
□ApplicableNot applicable
2. Basic situation of the company
- Company profile
Stock abbreviation Aosaikang stock code 002755
Stock Exchange Shenzhen Stock Exchange
Contact and Contact Information Secretary of the Board of Directors Securities Affairs Representative
Name Wang Yanyan
Office address: No. 699, Kejian Road, Jiangning Science Park, Nanjing
Phone 025-52292222
Email [email protected]
- Main accounting data and financial indicators
Whether the company needs to retroactively adjust or restate previous years’ accounting data
□YesNo
This reporting period is better than the same period last year
Increase or decrease in operating income in the same period last year (yuan) 871,048,409.88 1,007,412,827.96 -13.54% Net profit attributable to shareholders of listed companies (yuan) 120,632,469.85 159,987,130.87 -24.60% Net profit attributable to shareholders of listed companies excluding non-recurring gains and losses
106,513,653.24 140,970,093.12 -24.44% profit (yuan)
Net cash flow generated from operating activities (yuan) 148,475,993.53 422,919,702.87 -64.89% Basic earnings per share (yuan/share) 0.13 0.17 -23.53% Diluted earnings per share (yuan/share) 0.13 0.17 -23.53% Weighted average return on equity 3.81% 5.07% -1.26% at the end of this reporting period compared with the end of this reporting period at the end of the previous year
Increase or decrease in total assets at the end of the previous year (yuan) 4,388,606,619.23 4,517,084,990.26 -2.84% Net assets attributable to shareholders of listed companies (yuan) 3,224,672,134.42 3,215,395,506.54 0.29%
Summary of the 2026 Semi-Annual Report of Beijing Aosaikang Pharmaceutical Co., Ltd.
- Number of shareholders and shareholding status of the company
Unit: Share
Advantages of restoration of voting rights at the end of the reporting period
Total number of ordinary shareholders at the end of the reporting period 32,887 0 Total number of first-time shareholders (if any)
Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)
Holding limited Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held Sale conditions
Share Status Quantity
Number of shares
Nanjing Aosaikang Investment Management Co., Ltd.
Domestic non-state-owned legal persons 34.20% 317,470,588 0 Not applicable 0 Division
Weirui Development Co., Ltd. Overseas legal person 12.22% 113,382,352 0 Not applicable 0Jiangsu Suyang Investment Industrial Co., Ltd. Domestic non-state-owned legal person 11.91% 110,500,560 0 Not applicable 0Zhongyi Weiye Holdings Co., Ltd. Overseas legal person 11.40% 105,840,430 0 Not applicable 0Industrial Bank Co., Ltd.-Yong
Ying Pharmaceutical Innovation Smart Selection Hybrid Initiative Others 3.09% 28,691,167 0 N/A 0 Type Securities Investment Fund
Nanjing Haiji Investment Management Co., Ltd. Domestic non-state-owned legal person 0.96% 8,951,013 0 Not applicable 0 Bank of Shanghai Co., Ltd. - Bank
Huazhong Securities Innovative Drug Industry Transaction Type Other 0.66% 6,124,589 0 Not applicable 0 Open-ended index securities investment fund
China Construction Bank Corporation
- China Universal Innovative Pharmaceutical Theme Mixed Others 0.61% 5,690,900 0 N/A Type 0 Securities Investment Fund
Hong Kong Securities Clearing Company Limited Overseas legal person 0.60% 5,571,439 0 Not applicable 0 Chen Huili Domestic natural person 0.54% 4,990,376 0 Not applicable 0
Nanjing Aosaikang Investment Management Co., Ltd. and Weirui Development Co., Ltd. are acting in concert. Explanation of the above-mentioned shareholder related relationship or concerted action.
person; it is unknown whether there is a related relationship between other shareholders and whether they are persons acting in concert. Description of shareholders participating in margin trading and securities lending business (if any) Not applicable.
The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares
□ApplicableNot applicable
The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.
□ApplicableNot applicable
- Changes in controlling shareholders or actual controllers
Changes in controlling shareholders during the reporting period
□ApplicableNot applicable
The company's controlling shareholder did not change during the reporting period.
Changes in actual controller during the reporting period
□ApplicableNot applicable
The actual controller of the company did not change during the reporting period.
- Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders
□ApplicableNot applicable
The company has no preference shareholders’ shareholdings during the reporting period.
Summary of the 2026 Semi-Annual Report of Beijing Aosaikang Pharmaceutical Co., Ltd.
- Status of bonds existing on the date of approval of the semi-annual report
□ApplicableNot applicable
3. Important matters
For details, please refer to "Section 5 Important Events" of the company's "2026 Semi-Annual Report", which describes in detail the important events that occurred during the reporting period.